Please login to the form below
HTA
This page shows the latest HTA news and features for those working in and with pharma, biotech and healthcare.
Nature's way
Not to belittle recent advances or the brilliance of my colleagues in that area, but health technology assessment (HTA) is both harder and more difficult than drug or device safety assessment ... But our health economic capabilities are not there yet. If
Latest news
-
NICE launches consultation on its methods of drug evaluation
diagnostics. The health technology assessment (HTA) agency launched a public consultation last week on a proposal for changes to the methods it uses to evaluate potential medical treatments. ... The HTA agency has already identified potential areas for
-
Centre for Innovation in Regulatory Science awarded $1.09m Gates Foundation grant
health technology assessment (HTA) policies and processes.
-
NICE International relaunches, will offer advisory services
NICE has become one of the world’s most prominent and well-know health technology assessment (HTA) bodies since its inception in 1999. ... NICE International will build on the expertise of those within the organisation and draw on links with academic
-
NICE’s long-serving chief exec Sir Andrew Dillon to step down
NICE quickly became the world’s best-known and most prominent health technology assessment (HTA) body, and has set the standard for many other national institutes set up since then.
-
Who's calling the shots in European healthcare?
2019 has already been very eventful in terms of the debate about pharma’s future, including the question of how to proceed with plans for harmonisation of health technology assessment (HTA)
NICE launches consultation on its methods of drug evaluation
Centre for Innovation in Regulatory Science awarded $1.09m Gates Foundation grant
NICE’s long-serving chief exec Sir Andrew Dillon to step down
Who's calling the shots in European healthcare?
More from news
Approximately 32 fully matching, plus 151 partially matching documents found.
Latest Intelligence
-
Product launches: making the most of your one shot
Unexpected events – whether new evidence emerging from clinical trials, regulatory approval letters or HTA assessments, for example – should be expected.
-
Market shaping for better healthcare decisions
In addition, many global HTA bodies are at capacity with the reviews they are being commissioned to undertake, making an expensive, involved and long process even lengthier.
-
Assessing the impact of disease prevalence on access and pricing of rare disease drugs in England
This is especially the case in markets using cost-effectiveness analysis (CEA) for their health technology assessments (HTA). ... NICE formally incorporates the value of disease rarity in its HTAs by increasing the willingness to pay threshold for
-
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Establishing value, of course, necessitates assessment – whether that’s through a health technology assessment (HTA) style procedure or something else.
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
The access landscape is further complicated because many health technology assessment (HTA) methodologies are currently not geared up to evaluate these treatments. ... Yet NICE and many other HTA bodies limit their assessment to the cost-effectiveness of
Product launches: making the most of your one shot
Market shaping for better healthcare decisions
Assessing the impact of disease prevalence on access and pricing of rare disease drugs in England
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Great expectations: the urgent need for common purpose in Alzheimer’s disease
More from intelligence
Approximately 14 fully matching, plus 65 partially matching documents found.
Latest appointments
-
Open Access Consulting appoints new director
value dossiers, payer-focused objection handlers, stand-alone payer value propositions and local HTA submissions.
-
Claes Buxfeldt joins NDA
He becomes its new HTA director. AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board. ... Buxfeldt’s new role at NDA will see him drive and develop the group’s service offerings in the HTA
-
Professor Carole Longson moves from NICE to the ABPI
She most recently spent the 18 years at the National Institute for Health and Care Excellence ( NICE), where she has led the HTA organisation’s technology appraisal programme.
-
VCLS appoints Carole Jones to senior market access role
her focus on expanding the company’s market access capabilities, spanning payer strategy, health economics and outcomes research (HEOR), health technology assessment (HTA) and communications support.
-
EFPIA's Richard Torbett to move to the ABPI
At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.
Open Access Consulting appoints new director
Claes Buxfeldt joins NDA
VCLS appoints Carole Jones to senior market access role
EFPIA's Richard Torbett to move to the ABPI
More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Market Shaping for Better Healthcare Decisions
In addition, many global HTA bodies are at capacity with the reviews they are being commissioned to undertake, making an expensive, involved and long process even lengthier.
-
Real-world evidence: breaking boundaries in rare disease
patients. When it comes to rare disease, you need real-world evidence.”. However, we are just starting to understand the power of RWE and many stakeholders, including payers, HTA bodies and
-
Let's be ambitious for patients and life sciences investment in Global Britain
But the UK also needs an HTA system fit for the future. ... From the Cancer Drugs Fund to the promised Innovation Drugs Fund, initiatives have been created as technical ‘work-arounds’ for NICE and for an HTA system that has not kept pace
-
Digital Therapeutics Landscape in Europe
OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK.
-
Tapping the potential of rare diseases: A journey into uncharted territory
Costs per treatment can often be high, and this must be effectively justified to payors through the appropriate HTA or equivalent route.
Let's be ambitious for patients and life sciences investment in Global Britain
Digital Therapeutics Landscape in Europe
More from PMHub
Approximately 6 fully matching, plus 19 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Digital account director
-
Competitive
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
- Merck & Co's cancer drug Keytruda gaining traction in US
- Tyson Fury takes on his Invisible Opponent in hard hitting ad for suicide prevention charity Campaign Against Living Miserably
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
